Aim Immunotech INC. (AIM) — 8-K Filings

All 8-K filings from Aim Immunotech INC.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

AIM ImmunoTech Files 8-K on Shareholder Vote Matters — Dec 17, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on December 17, 2025, reporting on matters submitted to a vote of security holders as of December 16, 2025. The filing does not
AIM ImmunoTech Enters Material Definitive Agreement — Nov 19, 2025 Risk: medium
On November 18, 2025, AIM ImmunoTech Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as H
AIM ImmunoTech Files 8-K for Material Agreement — Oct 29, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on October 29, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibits. The
AIM ImmunoTech Files 8-K with Financials — Oct 20, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on October 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
AIM ImmunoTech Files 8-K for Material Agreement — Jul 31, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on July 30, 2025, reporting the entry into a material definitive agreement. The filing also includes other events and financial
AIM ImmunoTech Files 8-K — Jul 28, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on July 28, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is
AIM ImmunoTech Faces Delisting Concerns — Jun 20, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on June 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule on June 17, 2025. The filing a
AIM ImmunoTech Inc. Files 8-K Amid Listing Concerns — Jun 12, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on May 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also filed amendme
AIM ImmunoTech Files 8-K on Shareholder Votes and Financials — May 1, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 30, 2025. The
AIM ImmunoTech Faces Delisting Concerns — Apr 7, 2025 Risk: high
AIM ImmunoTech Inc. filed an 8-K on April 7, 2025, reporting events as of April 4, 2025. The filing indicates a potential notice of delisting or failure to meet
AIM ImmunoTech Files 8-K for Material Agreement — Apr 4, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on April 4, 2025, reporting a material definitive agreement and financial statements. The filing pertains to the period ending
AIM ImmunoTech Files 8-K Current Report — Feb 28, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 28, 2025, reporting an event on February 26, 2025. The filing is a current report under Section 13 or 15(d) of the
AIM ImmunoTech Files 8-K on Officer/Director Changes & Financials — Feb 26, 2025 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on February 26, 2025, reporting on events as of February 24, 2025. The filing covers the departure of directors or certain offi
AIM ImmunoTech Files 8-K — Feb 11, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc.
AIM ImmunoTech Files 8-K — Feb 7, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc.,
AIM ImmunoTech Files 8-K — Feb 5, 2025 Risk: low
AIM ImmunoTech Inc. filed an 8-K report on February 5, 2025, to disclose other events and financial statements. The filing does not contain specific financial f
AIM ImmunoTech Appoints New Chief Medical Officer — Dec 23, 2024 Risk: medium
AIM ImmunoTech Inc. announced on December 19, 2024, the appointment of Dr. Michael J. Harbut as Chief Medical Officer. Dr. Harbut brings extensive experience in
AIM ImmunoTech Files 8-K on Shareholder Vote Matters — Dec 20, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on December 20, 2024, reporting on matters submitted to a vote of its security holders on December 17, 2024. The filing details
AIM ImmunoTech Files 8-K: Regulation FD, Other Events — Nov 27, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on November 27, 2024, reporting on events that occurred on November 25, 2024. The filing includes information related to Regula
AIM ImmunoTech Files 8-K: Agreements, Equity Sales, and Financials — Oct 1, 2024 Risk: medium
AIM ImmunoTech Inc. filed an 8-K on September 30, 2024, reporting on a material definitive agreement, unregistered sales of equity securities, and other events.
AIM ImmunoTech CFO Departs, New Director Appointed, $10M Stock Sale — Sep 12, 2024 Risk: medium
AIM ImmunoTech Inc. announced on September 11, 2024, the departure of its Chief Financial Officer, Elizabeth L. McGovern, effective September 10, 2024. The comp
AIM ImmunoTech Files 8-K for Bylaw Amendments & Financials — Aug 1, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on July 31, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, former
AIM ImmunoTech Sells Ampligen Business for $10M — Jul 15, 2024 Risk: medium
AIM ImmunoTech Inc. announced on July 12, 2024, that it has entered into a definitive agreement to sell its Ampligen business to a subsidiary of Grand River Pha
AIM ImmunoTech Raises $10M, Secures New Credit Line — Jun 3, 2024 Risk: medium
AIM ImmunoTech Inc. announced on May 31, 2024, the closing of a previously disclosed private placement of common stock, raising approximately $10.0 million in g
AIM ImmunoTech Enters Material Agreement, Creates Financial Obligation — Feb 20, 2024 Risk: medium
AIM ImmunoTech Inc. entered into a Material Definitive Agreement on February 16, 2024, which also created a Direct Financial Obligation for the company. The fil
AIM ImmunoTech Files Routine 8-K for Reg FD & Exhibits — Feb 9, 2024 Risk: low
AIM ImmunoTech Inc. filed an 8-K on February 8, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing
AIM ImmunoTech Updates Corporate Address in 8-K Filing — Jan 25, 2024
AIM ImmunoTech Inc. filed an 8-K on January 25, 2024, primarily to update its corporate address to 2117 SW Highway 484, Ocala, FL 34473, and confirm its telepho
AIM ImmunoTech Files 8-K for Regulation FD Disclosure — Jan 10, 2024
AIM ImmunoTech Inc. filed an 8-K on January 10, 2024, primarily to disclose information under Regulation FD. This filing indicates that the company is making ce

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX